Morgan Stanley Starts Exscientia PLC (EXAI) at Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
UPDATE: BofA Securities Starts Exscientia PLC (EXAI) at Buy on AI Enabled Drug Platform
October 26, 2021 6:07 AM EDT(Updated - October 27, 2021 7:27 AM EDT)
BofA Securities analyst Michael Ryskin initiates coverage on Exscientia PLC (NASDAQ: EXAI) with a Buy rating and a price target of $27.00.
The analyst stated "Exscientia is a tech-enabled drug discovery platform company, leveraging artificial... More



